René Russo, Xilio CEO (Alicia Petitti for Xilio)

Xilio Ther­a­peu­tics goes pub­lic as bio­phar­ma IPOs rum­ble for­ward in Q4

It’s been a busy fall on Wall Street — and this week, we’ve got an­oth­er biotech go­ing pub­lic af­ter Ven­tyx yes­ter­day.

Mass­a­chu­setts sol­id-tu­mor biotech Xilio Ther­a­peu­tics made its pub­lic de­but to­day, join­ing 149 oth­er biotechs that have gone pub­lic so far this year.

Back on Oc­to­ber 1st, Xilio filed its S-1 with the SEC to make its IPO de­but for $100 mil­lion — the next step in fi­nanc­ing af­ter com­plet­ing a $95 mil­lion Se­ries C back in Feb­ru­ary.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.